Skip to main content

Day: April 21, 2020

Appian kondigt Appian World 2020 Virtual Edition aan op 12 en 13 mei 2020

AMSTERDAM, The Netherlands , April 21, 2020 (GLOBE NEWSWIRE) — Appian zal op 12 en 13 mei 2020 de virtuele editie van Appian World 2020 organiseren. Het virtuele evenement van dit jaar geeft elke deelnemer de beste plek voor ‘s werelds belangrijkste conferentie over low-code automatisering. Registreren kan kosteloos op https://ap.pn/3crB7qw.De agenda staat vol met live en on-demand presentaties over Artificial Intelligence, Robotic Process Automation, low-code ontwikkeling, cloud beveiliging, DevOps, IT governance en nog veel meer. Sessies over Appian’s gratis COVID-19 applicatie en andere toepassingen zullen laten zien waarom low-code automatisering juist nu van essentieel belang is in tijden van verandering.Keynote sprekers zijn onder andere:Kristie Grinnell, VP, Global CIO en Chief Supply Chain Officer, General Dynamics...

Continue reading

Appian kündigt Appian World Virtual Edition für den 12. und 13. Mai 2020 an

FRANKFURT, Germany, April 21, 2020 (GLOBE NEWSWIRE) — Appian (NASDAQ: APPN) veranstaltet am 12. und 13. Mai 2020 die virtuelle Ausgabe der Appian World 2020. Bei der diesjährigen virtuellen Veranstaltung erhält jeder Teilnehmer einen Platz in der ersten Reihe für die weltweit führende Konferenz zum Thema Low-Code-Automatisierung. Interessenten können sich kostenlos registrieren unter https://ap.pn/3crB7qw.Das Programm ist gespickt mit Live- und On-Demand-Präsentationen zu einer Vielzahl interessanter Themen. Dazu gehören beispielsweise künstliche Intelligenz (KI), Robotic Process Automation (RPA), Prozess-Automatisierung, Low-Code-Entwicklung, Cloud Security, DevOps oder IT-Governance. Demos zur kostenlosen COVID-19 Anwendung von Appian und anderen Lösungen zeigen, wieso Low-Code-Automatisierung in Zeiten des Wandels unerlässlich...

Continue reading

Datametrex Provides Update On Health Canada Submission & Welcomes Advisors

TORONTO, April 21, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF ) wishes to provide additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea. An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020.As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on March 18, 2020. This Interim Order (IO) will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada.The Company...

Continue reading

Progress on completion of conventional cash transaction

21 April 2020G4S plcProgress on completion of conventional cash transactionG4S, the leading global security company is pleased to report that it has now completed and received approximately 64% of the proceeds anticipated from the sale of its conventional cash businesses to The Brink’s Company (“Brink’s”) that was announced on 26 February 2020.  Under the agreement with Brink’s, the Group has sold the majority of its conventional cash businesses for an enterprise value of £727 million, with expected net cash proceeds of approximately £670 million. The substantial majority of the remaining completions are scheduled to occur during 2020.The sale of the majority of the conventional cash businesses greatly enhances the Group’s strategic, commercial and operational focus and strengthens further its financial position.As reported in our 2019...

Continue reading

CDK GLOBAL TO ANNOUNCE THIRD QUARTER FISCAL 2020 FINANCIAL RESULTS ON MAY 5, 2020

HOFFMAN ESTATES, Ill., April 21, 2020 (GLOBE NEWSWIRE) — CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal third quarter ended March 31, 2020 after the closing of the Nasdaq market on Tuesday, May 5, 2020.CDK will also be hosting a conference call at 4:00 p.m. CT on May 5, 2020 to discuss the results for the fiscal quarter. Brian Krzanich, chief executive officer, Joe Tautges, executive vice president and chief financial officer, and Julie Schlueter, director investor relations, will be participating on the call.Investors and interested participants are invited to listen to the conference call via live webcast, which can be accessed through the CDK Investor Relations home page, https://investors.cdkglobal.com. A supplemental slide presentation...

Continue reading

Mise à jour supplémentaire sur l’usage compassionnel de l’opaganib en Israël fourni par Redhill Biopharma

Chacun des cinq patients a enregistré une amélioration de la protéine C-réactive, quatre d’entre eux présentant également des améliorations cliniques mesurables, y compris une meilleure oxygénation requise et un nombre de lymphocytes plus élevé—L’opaganib a été administré aux cinq patients en plus des soins standard, y compris le traitement de fond à base d’hydroxychloroquine, et a été bien toléré—Le mécanisme d’action unique de l’opaganib a des activités à la fois antivirales et anti-inflammatoires, ciblant un facteur hôte critique, minimisant le développement potentiel de la résistance due aux mutations virales—Le plan d’usage compassionnel en Italie s’apprête à passer au stade d’étude clinique, conformément au changement mondial visant à générer des données plus solides...

Continue reading

RedHill Biopharma legt neue Ergebnisse aus dem Härtefallprogramm mit Opaganib zur Behandlung von COVID-19 -Patienten in Israel vor

Alle fünf Patienten zeigten verbesserte CRP-Werte. Vier der fünf Patienten wiesen zudem eine messbare Verbesserung des klinischen Zustands auf, einschließlich der erforderlichen zusätzlichen Oxygenierung und höheren Lymphozytenzahlen—Opaganib wurde allen fünf Patienten zusätzlich zur Standardtherapie, einschließlich einer Hydroxychloroquin-Hintergrundtherapie, verabreicht und erwies sich als gut verträglich.—Der einzigartige Wirkmechanismus von Opaganib mit antiviralen und entzündungshemmenden Eigenschaften, zielt auf einen wichtigen Wirtsfaktor ab und minimiert die potenzielle Entwicklung von Resistenzen aufgrund von Virusmutationen—Das geplante Härtefallprogramm in Italien soll in eine klinische Studie umgewandelt werden – im Einklang mit dem globalen Trend, für regulatorische Zwecke zuverlässigere Daten in Prüfzentren...

Continue reading

IMImobile offers free eClinic software amid pandemic

LONDON, April 21, 2020 (GLOBE NEWSWIRE) — Global cloud communications software and solutions provider IMImobile PLC, today announces that its healthcare division, Healthcare Communications, has launched its eClinic software to NHS trusts for free for a year. The video consultation software allows for patients to see their clinicians via online consultations, from the comfort and safety of their own homes. This means that regular health checks and medical reporting can continue even if patients or healthcare professionals are self-isolating.Kenny Bloxham, Managing Director at Healthcare Communications, says: “We all need to support the NHS through this crisis; by switching as many appointments to virtual as possible, we can ensure services are not overwhelmed in the future. The eClinic solution is clinician led, so patients don’t...

Continue reading

Aktian tammi–maaliskuun osavuosikatsaus julkistetaan tiistaina 5.5.2020 klo 8.00

Aktia Pankki OyjLehdistötiedote21.4.2020 klo 10.00Aktian tammi–maaliskuun osavuosikatsaus julkistetaan tiistaina 5.5.2020 klo 8.00Aktian tammi–maaliskuun 2020 osavuosikatsaus julkistetaan tiistaina 5.5.2020 klo 8.00. Osavuosikatsaus on saatavilla julkistuksen jälkeen Aktian verkkosivuilla osoitteessa www.aktia.com.Webcast-lähetys tulostilaisuudestaAktian tulostilaisuudesta järjestetään suora webcast-lähetys tiistaina 5.5.2020 klo 10.00. Toimitusjohtaja Mikko Ayub ja talous- ja rahoitusjohtaja Outi Henriksson esittelevät tuloksen. Tilaisuus pidetään englanniksi ja sitä voi seurata suorana webcast-lähetyksenä tai tallenteena tilaisuuden jälkeen osoitteessa https://aktia.videosync.fi/2020-q1-results. Englanninkielinen esitysmateriaali on saatavilla ennen tulostilaisuutta Aktian verkkosivuilla osoitteessa www.aktia.com.Aktia Pankki OyjLisätietoja:Lotta...

Continue reading

Aktias delårsrapport för januari–mars publiceras tisdagen 5.5.2020 kl. 8.00

Aktia Bank AbpPressmeddelande21.4.2020 kl. 10.00Aktias delårsrapport för januari–mars publiceras tisdagen 5.5.2020 kl. 8.00Aktias delårsrapport för januari–mars 2020 publiceras tisdagen 5.5.2020 kl. 8.00. Delårsrapporten finns tillgänglig på Aktias webbplats på adressen www.aktia.com efter publiceringen.Webcast-sändning från resultattillställningenEn direkt webcast-sändning arrangeras från Aktias resultattillställning tisdagen 5.5.2020 kl. 10.00. Verkställande direktör Mikko Ayub och ekonomi- och finansdirektör Outi Henriksson presenterar resultatet. Tillställningen hålls på engelska och kan ses som en direkt webcast-sändning eller en inspelning efter tillställningen på adressen https://aktia.videosync.fi/2020-q1-results. Presentationsmaterialet på engelska finns tillgängligt på Aktias webbplats www.aktia.com före resultattillställningen.Aktia...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.